Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …

The introduction of in vivo imaging of Aβ-amyloid (Αβ) pathology more than a decade ago,
transformed the assessment of Alzheimer disease (AD) allowing the evaluation of Aβ …

Alzheimer's disease (AD) is the most common form of dementia characterized
neuropathologically by senile plaques and neurofibrillary tangles (NFTs). Early …

Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect
Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease …

Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …

Aggregated tau protein is a major neuropathological substrate central to the
pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD) …

Although the diagnosis of dementia is still largely a clinical one, based on history and
disease course, neuroimaging has dramatically increased our ability to accurately diagnose …

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …

In vivo imaging of tau pathology will provide new insights into tau deposition in the human
brain, thus facilitating research into causes, diagnosis and treatment of major dementias …